Skip to main content
. 2018 Mar 19;128(4):1657–1670. doi: 10.1172/JCI94331

Figure 3. Genes differentially detected in RTX-treated ganglia across experiments in 3 species.

Figure 3

Data from 7 experiments were mined and analyzed, including 3 experiments in which the TRPV1 agonist RTX was used to selectively damage TRPV1+ neurons in the same manner as in the heatmap in Figure 2. Genes were filtered to show only those genes decreasing by at least 20% in human, dog, and rat RTX-treated samples. Genes that are also decreased by at least 30% in all samples are shown in bold orange. The 1 gene (KLHL1) expressed at ≥40% is shown in bold red.